Proficio Capital Partners LLC increased its stake in Johnson & Johnson (NYSE:JNJ) by 20.8% in the first quarter, Holdings Channel reports. The institutional investor owned 13,906 shares of the company’s stock after acquiring an additional 2,394 shares during the quarter. Proficio Capital Partners LLC’s holdings in Johnson & Johnson were worth $2,035,000 as of its most recent SEC filing.
Several other large investors also recently modified their holdings of JNJ. Houlihan Financial Resource Group Ltd. bought a new stake in Johnson & Johnson during the fourth quarter valued at $1,376,000. Bowen Hanes & Co. Inc. increased its stake in Johnson & Johnson by 11.5% during the fourth quarter. Bowen Hanes & Co. Inc. now owns 362,432 shares of the company’s stock valued at $52,868,000 after purchasing an additional 37,290 shares during the last quarter. Community Financial Services Group LLC increased its stake in Johnson & Johnson by 2.6% during the fourth quarter. Community Financial Services Group LLC now owns 25,571 shares of the company’s stock valued at $3,730,000 after purchasing an additional 645 shares during the last quarter. Chelsea Counsel Co. increased its stake in Johnson & Johnson by 3.9% during the fourth quarter. Chelsea Counsel Co. now owns 45,344 shares of the company’s stock valued at $6,614,000 after purchasing an additional 1,693 shares during the last quarter. Finally, Csenge Advisory Group increased its stake in Johnson & Johnson by 18.7% during the fourth quarter. Csenge Advisory Group now owns 13,480 shares of the company’s stock valued at $1,966,000 after purchasing an additional 2,127 shares during the last quarter. Institutional investors and hedge funds own 67.66% of the company’s stock.
In other Johnson & Johnson news, Director William D. Perez purchased 500 shares of the business’s stock in a transaction on Friday, March 13th. The stock was bought at an average cost of $127.69 per share, with a total value of $63,845.00. Following the acquisition, the director now owns 16,030 shares of the company’s stock, valued at $2,046,870.70. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.27% of the stock is currently owned by corporate insiders.
JNJ stock opened at $144.37 on Friday. The company has a market capitalization of $386.52 billion, a P/E ratio of 19.10, a PEG ratio of 3.19 and a beta of 0.71. The company has a 50-day simple moving average of $146.81 and a 200 day simple moving average of $142.30. Johnson & Johnson has a fifty-two week low of $109.16 and a fifty-two week high of $157.00. The company has a quick ratio of 1.05, a current ratio of 1.31 and a debt-to-equity ratio of 0.41.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, April 14th. The company reported $2.30 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.03 by $0.27. Johnson & Johnson had a net margin of 24.47% and a return on equity of 39.71%. The company had revenue of $20.69 billion during the quarter, compared to the consensus estimate of $19.48 billion. During the same period in the prior year, the company earned $2.10 EPS. Johnson & Johnson’s revenue was up 3.3% on a year-over-year basis. Equities analysts anticipate that Johnson & Johnson will post 7.68 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 9th. Shareholders of record on Tuesday, May 26th will be issued a $1.01 dividend. This represents a $4.04 dividend on an annualized basis and a yield of 2.80%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $0.95. The ex-dividend date is Friday, May 22nd. Johnson & Johnson’s dividend payout ratio is presently 43.78%.
Several analysts have weighed in on JNJ shares. Barclays boosted their target price on shares of Johnson & Johnson from $173.00 to $182.00 and gave the company an “overweight” rating in a research note on Wednesday, April 29th. SVB Leerink lowered their target price on shares of Johnson & Johnson from $172.00 to $160.00 and set an “outperform” rating for the company in a research note on Wednesday, April 8th. Citigroup upped their price target on shares of Johnson & Johnson from $150.00 to $165.00 and gave the stock a “buy” rating in a research report on Wednesday, April 15th. Wells Fargo & Co upgraded shares of Johnson & Johnson to a “hold” rating in a research report on Wednesday, April 22nd. Finally, Raymond James upped their price target on shares of Johnson & Johnson from $153.00 to $157.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 15th. Four research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. The company has an average rating of “Buy” and an average price target of $163.47.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Recommended Story: How are dividend achievers different from dividend aristocrats?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.